Prior authorization required

Prior authorization is required for V-Go, Omnipod (all versions including Omnipod DASH and Omnipod 5), and the InPen system; the provider must demonstrate the member meets all approval criteria by submitting supporting clinical information.

Authorization and quantity limits

Prior authorization requests must adhere to the policy's quantity limits: Omnipod Pods are limited to 10 Pods per month (requests >10 require clinical rationale and documentation); InPen is limited to one system per year; V-Go quantity limits and renewal durations vary by line of business.

• Omnipod Pods: ≤10 per month; clinical rationale required for >10/month (chunk 19).
• InPen: ≤1 system per year (chunk 19).
• Approval durations differ by line of business (Medicaid/HIM vs Commercial) (chunk 20).

Coding references for authorization

The policy references specific HCPCS and related supply codes for billing and coding guidance (e.g., E0784 for external ambulatory insulin delivery systems and A9274/A4211 for device/supplies); inclusion of codes is informational and does not guarantee coverage.

• E0784: External ambulatory insulin delivery system (chunk 52).
• A9274 / A4211 referenced for device and supply mapping (chunk 54).
• Providers should reference current professional coding guidance prior to claim submission (chunk 52).

Coding relevant to authorization

HCPCS codes cited in the policy include A4211, A9274, and E0784 for supplies and systems; note that S5561 is listed in the coding section as NOT applicable to the InPen.

• A4211: supplies for self-administered injection (may apply to InPen) (chunk 54).
• A9274: V-Go / Omnipod system mapping (chunk 54).
• E0784: external ambulatory insulin delivery system (chunk 54).
• S5561: does NOT apply to InPen (chunk 54).

Prior therapy requirement (≥6 months)

For initial approval, the member must have used either a continuous insulin delivery system or multiple daily injections for at least the prior 6 months before initiating the requested device.

• Continuous insulin delivery system for ≥6 months OR
• Multiple daily insulin injections (≥3 injections/day) for ≥6 months with history of suboptimal control (chunk 13).

Consider therapeutic alternatives

Therapeutic alternatives (other insulin pumps and insulin products) are listed in Appendix B and may be considered or recommended in the approval process as alternative options.

• Appendix B lists continuous insulin delivery systems and pump alternatives that may be preferred or recommended (chunk 24).

Policy history and updates

Policy history notes the document was adapted from CP.PHAR.505 and updated to add InPen and, later, Omnipod 5; no additional step therapy rules are specified in the cited history.

• Adapted from CP.PHAR.505; InPen added; Omnipod 5 added in 2Q 2022 (chunk 55).

Step therapy: none specified

The document specifies no formal step therapy sequence in the cited sections; it documents additions and adaptations (InPen, Omnipod 5) but does not impose step-failure requirements beyond prior therapy and alternatives references.

• No explicit step-failure requirements are listed in these sections (chunks 54, 55).

Required clinical documentation

Providers must submit documentation — such as office chart notes, laboratory results, and other clinical information — that demonstrates the member meets all approval criteria at the time of prior authorization request.

• Examples: office notes, lab results, and other clinical information supporting criteria (chunk 12).

Documentation required for overrides (>standard quantities)

When requesting quantities above the policy limits (for example, more than 10 Omnipod Pods per month), the provider must include a clinical rationale and supporting documentation to justify the higher quantity.

• Requests >10 Pods/month require clinical rationale and documentation (chunk 19).
• Off‑label or other diagnoses may need documentation per off‑label use policies (chunk 21).

Reference device documentation

The policy cites device-specific FDA 510(k) summaries and manufacturer user guides (Omnipod, Omnipod DASH, Omnipod 5, InPen, V-Go) as reference materials that providers may use to support authorization requests.

• V-Go 510(k) summary referenced (chunk 37).
• Omnipod user guides and Omnipod 5 user guide referenced (chunk 43).
• InPen instructions for use referenced (chunk 47).

Follow Health Plan administrative policies

Providers must follow all Health Plan terms, conditions, exclusions, limitations, and applicable administrative policies and procedures; the effective date of the policy is as determined by the Health Plan and coverage is subject to contractual terms.

• Coverage decisions subject to coverage documents, state/federal requirements, and Health Plan administrative policies (chunks 56, 58).

Denial risk: insufficient documentation

Failure to submit the required supporting documentation (office notes, labs, or other clinical information) demonstrating the member meets approval criteria may result in denial of the request.

Denial risk: exceeding quantity limits

Requests that exceed the policy's standard quantity limits (for example, more than 10 Omnipod Pods per month or more than one InPen per year) require clinical justification and may be denied if adequate rationale and documentation are not provided.

• Exceeding 10 Pods/month requires clinical rationale (chunk 19).
• Non‑FDA indications not addressed by policy require off‑label documentation per off‑label policies and may be denied (chunk 22).

Coding-related denials possible

Coverage and reimbursement are subject to coding guidance; listing or omission of a code in the policy is informational and does not guarantee coverage or payment.

• Codes are for informational purposes; providers should use current coding guidance (chunk 52).
• Inclusion/exclusion of codes does not guarantee coverage and may affect reimbursement (chunk 54).

Medicaid precedence may alter coverage

For Medicaid members, state Medicaid coverage provisions take precedence over the clinical policy when there is a conflict; providers should consult the state Medicaid manual for applicable coverage rules.

Benefit: medical benefit coverage

This policy applies to devices covered under the medical benefit for Commercial, Medicaid, and HIM lines of business per the policy header.

• Policy header lists Commercial, Medicaid, HIM medical benefit applicability (chunk 0).

Devices intended for home/outpatient use

Devices are intended for outpatient/home use with appropriate training; Omnipod 5 integrates with the Dexcom G6 CGM for Automated Mode functionality.

• Omnipod 5 communicates with Dexcom G6 and uses CGM values for Automated Mode (chunk 33).
• User guides describe outpatient/home use and training for device initiation (chunk 30).

Distribution and coding note for Omnipod DASH/5

Omnipod DASH and Omnipod 5 are available only through pharmacy distribution per the coding note; E0784 is described as an external ambulatory insulin delivery system used to reference Pod devices.

• A9274 and E0784 notes: Omnipod DASH and Omnipod 5 do not use those codes and are pharmacy‑distributed (chunk 54).
• E0784 described as external ambulatory insulin delivery system (chunk 52).